Biosimilar Newsletter Archive

  1. 11.02.22 -- Reduce Risk Of Drug Product Filing Delays 11/2/2022

    11/02/22 Biosimilar Development Newsletter

  2. 10.27.22 -- Innovative Solutions For mRNA, Bispecific Antibodies, Viral Vectors, And More 10/27/2022

    10/27/22 Biosimilar Development Newsletter

  3. 10.27.22 -- Cardinal Health Report: Rheumatologist Confidence In Biosimilars Increasing 10/27/2022
    10/27/22 Biosimilar Development Newsletter
  4. 10.24.22 -- New Therapies Require New Development Approaches And Regulatory Interactions 10/24/2022

    10/24/22 Biosimilar Development Newsletter

  5. 10.20.22 -- Amgen Report Finds Biosimilar Competition Saved US $21B 10/20/2022
    10/20/22 Biosimilar Development Newsletter
  6. 10.19.22 -- Steps To Shore Up The Biopharma Supply Chain 10/19/2022

    10/19/22 Biosimilar Development Newsletter

  7. 10.14.22 -- Evolving Design Space Requirements For Biologic Combination Products 10/14/2022

    10/14/22 Biosimilar Development Newsletter

  8. 10.13.22 -- FDA User Fee Reauthorization: CBER A Clear Winner 10/13/2022
    10/13/22 Biosimilar Development Newsletter
  9. 10.07.22 -- Time To Re-Think Your Buffer Management Strategy 10/7/2022

    10/07/22 Biosimilar Development Newsletter

  10. 10.06.22 -- Celltrion Receives FDA Approval For Avastin Biosimilar 10/6/2022
    10/06/22 Biosimilar Development Newsletter